677 материалов по теме, собраны автоматически из проверенных источников
The FDA approved combination imlunestrant plus abemaciclib for adults with hormone therapy-resistant estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. The combination therapy (Inluriyo and Verzenio, Eli Lilly & Co.) was approved with the indication for certain patients with…
U.S. FDA approves Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Investing News Network
Researchers at Wake Forest University School of Medicine have identified a protein that may help an aggressive form of breast cancer spread to the brain and escape the body's immune defenses.
Researchers uncover how aggressive breast cancer may spread to the brain | Newswise Newswise
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer Business Wire
Breast cancer has launched a new revolution in precision therapy. eu.36kr.com
A new study published in the journal npj Breast Cancer demonstrates that an artificial intelligence (AI) model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score. This research, conducted by a team from the ECOG-ACRIN Cancer…
Wait Times for Cancer Treatment Keep Getting Longer, Study Finds Breast Cancer.org
Study identifies key factors in breast cancer survivors' sexual recovery News-Medical
Women with a higher body mass index (BMI) in early adulthood may have a lower risk of developing breast cancer after menopause because of lasting changes in the structure of their breast tissue, according to researchers at The University of Manchester and Manchester University NHS Foundation Trust.
A new AI-powered test offers more accurate prediction of breast cancer recurrence risk EurekAlert!
Sexual well-being can often be overlooked during women's recovery from breast cancer, with many continuing to experience significant sexual and intimacy challenges long after treatment ends. Griffith University researchers interviewed 31 breast cancer survivors ages 32–72 and developed a three-layer model of…